drugset / Trial / NCT07471867
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.
Timeline
- Start
- 2026-04-02
- Primary completion
- 2028-07-12
- Completion
- 2028-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rabeprazole | Small molecule | 10 mg | Oral |
| Subject | Zastaprazan | Unknown | 20 mg | Oral |